In the event of a dog bite, a person needs more than just the rabies vaccine. Experts highlight the importance of ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...